Multiply Labs, a robotics company developing automated manufacturing systems to produce individualized drugs, and Akron Bio, a supplier of critical materials and services for advanced therapies, announced a non-exclusive partnership focused on automating and standardizing the use of cytokines in cell therapy manufacturing.
Leveraging Multiply Labs' cell therapy robotic cluster, this partnership will enable Akron’s cytokines, starting with cGMP-compliant rHu Interleukin-2 (IL-2), to be automated with the use of robotics. Multiply Labs’ robotic systems will incorporate Akron’s liquid IL-2 into its cell therapy manufacturing workflow in an aseptic manner, precisely formulating and dispensing the right amount for any given process.
Akron and Multiply Labs will partner to integrate Akron’s existing cGMP-compliant cytokines with Multiply Labs’ proprietary adapter system, thereby making these materials compatible with Multiply Labs’ cell therapy robotic clusters. Manufacturers already using Akron’s products will be able to use these automated syringes with their current equipment, without substantially changing their overall process for cell therapy manufacturing.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!